Fig. 6.

Tumor growth inhibition of LAC117 in HepG2 HCC xenograft models. a, b After the tumors reached 50–100 mm³ in size, the mice received an intraperitoneal administration of LAC117 (100 μg/mL) once daily for 15 days (n = 4, each group). Tumor volume and body weight were measured every 3 days in HepG2 HCC xenograft mouse models. The average tumor volume in the vehicle- or LAC117-treated group was plotted. c, d The tumors were isolated from HepG2 xenograft model, and were weighed immediately. Data are expressed as the mean ± SEM (*P < 0.05 and **P < 0.01)